- Home
- NCMI vs SNY Comparison
NCMI vs SNY Comparison
Compare NCMI & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCMI
- SNY
- Stock Information
- Founded
- NCMI 2005
- SNY 1994
- Country
- NCMI United States
- SNY France
- Employees
- NCMI N/A
- SNY N/A
- Industry
- NCMI Advertising
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- NCMI Consumer Discretionary
- SNY Health Care
- Exchange
- NCMI Nasdaq
- SNY Nasdaq
- Market Cap
- NCMI 434.8M
- SNY 113.4B
- IPO Year
- NCMI 2007
- SNY N/A
- Fundamental
- Price
- NCMI $4.85
- SNY $47.68
- Analyst Decision
- NCMI Strong Buy
- SNY Buy
- Analyst Count
- NCMI 4
- SNY 4
- Target Price
- NCMI $7.00
- SNY $61.50
- AVG Volume (30 Days)
- NCMI 429.6K
- SNY 2.8M
- Earning Date
- NCMI 11-04-2025
- SNY 10-24-2025
- Dividend Yield
- NCMI 2.48%
- SNY 3.35%
- EPS Growth
- NCMI N/A
- SNY 118.56
- EPS
- NCMI N/A
- SNY 8.65
- Revenue
- NCMI $235,300,000.00
- SNY $53,714,621,258.00
- Revenue This Year
- NCMI $5.40
- SNY $1.53
- Revenue Next Year
- NCMI $14.48
- SNY $7.06
- P/E Ratio
- NCMI N/A
- SNY $5.52
- Revenue Growth
- NCMI 13.34
- SNY 15.65
- 52 Week Low
- NCMI $4.12
- SNY $44.73
- 52 Week High
- NCMI $7.60
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- NCMI 58.16
- SNY 47.66
- Support Level
- NCMI $4.72
- SNY $46.50
- Resistance Level
- NCMI $5.03
- SNY $47.69
- Average True Range (ATR)
- NCMI 0.19
- SNY 0.69
- MACD
- NCMI 0.06
- SNY -0.10
- Stochastic Oscillator
- NCMI 78.05
- SNY 49.44
About NCMI National CineMedia Inc.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.